CLAUD-IT’s Post

🚀 Exciting news from GE HealthCare! Congratulations to the team on receiving FDA approval for Flurpiridaz F-18 (Flyrcado), a groundbreaking PET imaging agent designed for adult patients with known or suspected coronary artery disease (CAD). 🎉 CAD is the leading cause of death in the U.S., often resulting from narrowed or blocked coronary arteries that can lead to serious conditions like myocardial ischemia and heart attacks. Flurpiridaz F-18 is a nuclear medicine tracer used in myocardial perfusion imaging (MPI) tests, which assess blood flow to the heart muscle under both rest and stress conditions. With its longer half-life of 109 minutes, Flurpiridaz F-18 offers improved diagnostic accuracy compared to the current standard of SPECT MPI, allowing for broader distribution and enhanced image quality. This advancement marks a significant leap forward in cardiac imaging, particularly for hard-to-image patients, such as those with high body mass index and women, for whom traditional imaging can be less accurate. 👉 Want to learn more about Flurpiridaz F-18 and its potential impact on cardiac care? Check out the full article here: https://lnkd.in/ghcPvEfN #HealthcareInnovation #NuclearMedicine #Cardiology #Radiopharmaceuticals

MinFound Medical oncology solution features two PET/CT systems, with excellent characteristics for various requirements, including cardio; and a wide aperture multi-modality CT scanner ScintCare e580-R. Nuclear medicine is a rapidly evolving field worldwide, with advancements in diagnostic imaging and therapeutic treatments. Collaboration between science, industry, and healthcare providers is driving innovation in nuclear medicine, with a focus on personalized medicine and targeted therapies. #molecularimaging #digitalpetct #SiPMdetector #PETdigitalgating #PETcalibration #oncologydiagnostics #imagingbeyondinfinity

Medical procedures regulating the execution of treatments are developed to ensure high precision in diagnostics and quality of care. They minimize the risk of side effects and maximize the benefits of modern medical techniques. This is particularly evident in cancer radiotherapy, where every moment and every millimeter matter for the health of patients. The Ministerstwo Zdrowia (Polish Ministry of Health) has published information about the expert teams responsible for developing these model medical radiological procedures for standard medical exposures. Our distinguished specialists, Dr. hab. Eng. Renata Kopeć, Professor at IFJ PAN, and MSc. Eng. Dawid Krzempek, who are dedicated to patient care at the Bronowice Cyclotron Center at The Henryk Niewodniczański Institute of Nuclear Physics Polish Academy of Sciences (IFJ PAN) and are advancing modern radiotherapeutic methods, have been appointed to the following teams: 💡 Proton beam radiotherapy for eye cancer 💡 Proton beam radiotherapy for cancers located outside the eye 💡 Proton beam radiotherapy for pediatric cancers We are confident that their contributions to the development of these standard medical radiological procedures will help elevate the standards of care in Poland. #IFJPAN #CCB #Protonotherapy #Radiotherapy #

MinFound Medical oncology solution features two PET/CT systems, with excellent characteristics for various requirements, including cardio; and a wide aperture multi-modality CT scanner ScintCare e580-R. Nuclear medicine is a rapidly evolving field worldwide, with advancements in diagnostic imaging and therapeutic treatments. Collaboration between science, industry, and healthcare providers is driving innovation in nuclear medicine, with a focus on personalized medicine and targeted therapies. #molecularimaging #digitalpetct #SiPMdetector #PETdigitalgating #PETcalibration #oncologydiagnostics #imagingbeyondinfinity

MinFound Medical oncology solution features two PET/CT systems, with excellent characteristics for various requirements, including cardio; and a wide aperture multi-modality CT scanner ScintCare e580-R. Nuclear medicine is a rapidly evolving field worldwide, with advancements in diagnostic imaging and therapeutic treatments. Collaboration between science, industry, and healthcare providers is driving innovation in nuclear medicine, with a focus on personalized medicine and targeted therapies. #molecularimaging #digitalpetct #SiPMdetector #PETdigitalgating #PETcalibration #oncologydiagnostics #imagingbeyondinfinity

At the Radiological Society of North America (RSNA) 2024 Annual Meeting, GE HealthCare unveils Aurora,* a new dual head SPECT/CT designed to help clinicians see and do more, aiming to help expand the range of CT procedures typically available in hybrid systems** and provide support for conditions, such as cancer and cardiac disorders, which rely on early detection and precise localization of abnormalities for effective intervention. Learn more: https://lnkd.in/gZAxiCvH #GEHealthCare #RSNA2024 #RSNA24 #FutureofHealthCare #PrecisionCare #MolecularImaging #SPECT *Aurora is CE marked. Available for sale in EU countries. 510(k) pending at the US FDA. Not available for sale in the U.S and other non-EU countries. **Aurora as compared to NM/CT 870 DR with Optima CT 540.

At the Radiological Society of North America (RSNA) 2024 Annual Meeting, GE HealthCare unveils Aurora,* a new dual head SPECT/CT designed to help clinicians see and do more, aiming to help expand the range of CT procedures typically available in hybrid systems** and provide support for conditions, such as cancer and cardiac disorders, which rely on early detection and precise localization of abnormalities for effective intervention. Learn more: https://lnkd.in/er5At2wT #GEHealthCare #RSNA2024 #RSNA24 #FutureofHealthCare #PrecisionCare #MolecularImaging #SPECT *Aurora is CE marked. Available for sale in EU countries. 510(k) pending at the US FDA. Not available for sale in the U.S and other non-EU countries. **Aurora as compared to NM/CT 870 DR with Optima CT 540.

At the Radiological Society of North America (RSNA) 2024 Annual Meeting, GE HealthCare unveils Aurora,* a new dual head SPECT/CT designed to help clinicians see and do more, aiming to help expand the range of CT procedures typically available in hybrid systems** and provide support for conditions, such as cancer and cardiac disorders, which rely on early detection and precise localization of abnormalities for effective intervention. Learn more: https://lnkd.in/gBCCExRZ #GEHealthCare #RSNA2024 #RSNA24 #FutureofHealthCare #PrecisionCare #MolecularImaging #SPECT *Aurora is CE marked. Available for sale in EU countries. 510(k) pending at the US FDA. Not available for sale in the U.S and other non-EU countries. **Aurora as compared to NM/CT 870 DR with Optima CT 540.

At the Radiological Society of North America (RSNA) 2024 Annual Meeting, GE HealthCare unveils Aurora,* a new dual head SPECT/CT designed to help clinicians see and do more, aiming to help expand the range of CT procedures typically available in hybrid systems** and provide support for conditions, such as cancer and cardiac disorders, which rely on early detection and precise localization of abnormalities for effective intervention. Learn more: https://lnkd.in/g_kVkscp #GEHealthCare #RSNA2024 #RSNA24 #FutureofHealthCare #PrecisionCare #MolecularImaging #SPECT *Aurora is CE marked. Available for sale in EU countries. 510(k) pending at the US FDA. Not available for sale in the U.S and other non-EU countries. **Aurora as compared to NM/CT 870 DR with Optima CT 540.

At the Radiological Society of North America (RSNA) 2024 Annual Meeting, GE HealthCare unveils Aurora,* a new dual head SPECT/CT designed to help clinicians see and do more, aiming to help expand the range of CT procedures typically available in hybrid systems** and provide support for conditions, such as cancer and cardiac disorders, which rely on early detection and precise localization of abnormalities for effective intervention. Learn more: https://lnkd.in/gWntJinm #GEHealthCare #RSNA2024 #RSNA24 #FutureofHealthCare #PrecisionCare #MolecularImaging #SPECT *Aurora is CE marked. Available for sale in EU countries. 510(k) pending at the US FDA. Not available for sale in the U.S and other non-EU countries. **Aurora as compared to NM/CT 870 DR with Optima CT 540.